The isothiocyanate sulforaphane modulates platelet function and protects against cerebral thrombotic dysfunction.

Autor: Gillespie S; Division of Brain Sciences, Imperial College London, London, UK., Holloway PM; Division of Brain Sciences, Imperial College London, London, UK.; Department of Molecular and Cellular Physiology, Louisiana State University Health Sciences Center - Shreveport, Shreveport, LA, USA., Becker F; Department of General, Visceral and Transplant Surgery, University Hospital Muenster, Muenster, Germany., Rauzi F; Platelet Biology Group, National Heart and Lung Institute, Imperial College London, London, UK., Vital SA; Department of Molecular and Cellular Physiology, Louisiana State University Health Sciences Center - Shreveport, Shreveport, LA, USA., Taylor KA; Platelet Biology Group, National Heart and Lung Institute, Imperial College London, London, UK., Stokes KY; Department of Molecular and Cellular Physiology, Louisiana State University Health Sciences Center - Shreveport, Shreveport, LA, USA., Emerson M; Platelet Biology Group, National Heart and Lung Institute, Imperial College London, London, UK., Gavins FNE; Department of Molecular and Cellular Physiology, Louisiana State University Health Sciences Center - Shreveport, Shreveport, LA, USA.; Department of Neurology, Louisiana State University Health Sciences Center - Shreveport, Shreveport, LA, USA.
Jazyk: angličtina
Zdroj: British journal of pharmacology [Br J Pharmacol] 2018 Aug; Vol. 175 (16), pp. 3333-3346. Date of Electronic Publication: 2018 Jul 03.
DOI: 10.1111/bph.14368
Abstrakt: Background and Purpose: Platelet activation provides a critical link between inflammation and thrombosis. Sulforaphane (SFN), a naturally occurring isothiocyanate, has been shown to display both anti-inflammatory and anti-thrombotic actions in the systemic microvasculature. As inflammation promotes thrombosis and vice versa, in this study we investigated whether SFN is able to reduce inflammatory potentiation of thrombotic events, suppress platelet activation and thrombus formation in the cerebral microvasculature.
Experimental Approach: Thrombosis was induced in the murine brain using the light/dye-injury model, in conjunction with LPS treatment, with and without SFN treatment. In vitro and in vivo platelet assays (aggregation, flow and other functional tests) were also employed, using both human and murine platelets.
Key Results: SFN was found to reduce LPS-mediated enhancement of thrombus formation in the cerebral microcirculation. In tail-bleed experiments, LPS treatment prolonged bleeding time, and SFN treatment was found to protect against this LPS-induced derangement of platelet function. SFN inhibited collagen-mediated platelet aggregation in vitro and in vivo and the associated adhesion and impaired calcium signalling. Furthermore, glycoprotein VI was shown to be involved in the protective effects observed with SFN treatment.
Conclusions and Implications: The data presented here provide evidence for the use of SFN in preventing stroke in selected high-risk patient cohorts.
(© 2018 The British Pharmacological Society.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje